Other Events ·
Nasdaq notifies CytoMed Therapeutics of non-compliance with $1.00 minimum bid price rule
GDTCCytoMed Therapeutics Ltd
The Nasdaq Stock Market notified CytoMed Therapeutics that its ordinary shares failed to maintain the required minimum bid price of $1.00 for 30 consecutive business days ending October 5, 2026. The company has a compliance period until April 5, 2027, to restore the share price to at least $1.00 for ten consecutive trading days. Failure to regain compliance may result in delisting proceedings or require a reverse stock split to meet listing standards. CytoMed Therapeutics is a clinical-stage biopharmaceutical company developing cell-based immunotherapies.